Sumarni, U.; Reidel, U.; Eberle, J.
Correction: Sumarni et al. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP. Cells 2021, 10, 987. Cells 2025, 14, 535.
https://doi.org/10.3390/cells14070535
AMA Style
Sumarni U, Reidel U, Eberle J.
Correction: Sumarni et al. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP. Cells 2021, 10, 987. Cells. 2025; 14(7):535.
https://doi.org/10.3390/cells14070535
Chicago/Turabian Style
Sumarni, Uly, Ulrich Reidel, and Jürgen Eberle.
2025. "Correction: Sumarni et al. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP. Cells 2021, 10, 987" Cells 14, no. 7: 535.
https://doi.org/10.3390/cells14070535
APA Style
Sumarni, U., Reidel, U., & Eberle, J.
(2025). Correction: Sumarni et al. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP. Cells 2021, 10, 987. Cells, 14(7), 535.
https://doi.org/10.3390/cells14070535